U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    46,650.86
    +196.52 (+0.42%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

On Nov 16, we issued an updated research report on Teleflex Incorporated TFX. The company continues to report strong growth in UroLift. However, escalating costs and expenses remain a major cause of worry. The stock currently carries a Zacks Rank #3 (Hold).

Over the past six months, Teleflex’s stock has underperformed its industry. The stock has gained 3.2% compared with the industry's 17.5% growth.

In the third quarter, on a year-over year basis, earnings and sales both declined significantly. Most of the segments registered revenue decline organically on a 12% aggregated negative impact from COVID-19. Margin debacle is another major concern. Teleflex is currently unable to ascertain the scope and duration of the pandemic as well as quantify the actual impact.

Teleflex Incorporated Price

Teleflex Incorporated Price
Teleflex Incorporated Price

Teleflex Incorporated price | Teleflex Incorporated Quote

The company also anticipates material disruption caused by the evolving COVID-19 pandemic and macroeconomic environment. It further expects significant adverse financial impact of the coronavirus pandemic. This time too the company has not provided its 2020 outlook.

On a positive note, in the third quarter, in terms of UroLift, the response to the company’s national DTC campaign exceeded expectations. Web traffic increased more than 150% since the launch and another encouraging metric is that multiple urologists are now motivated to get trained on UroLift as a result of patient requests due to the campaign.

In terms of UroLift 2, since the FDA clearance on Jul 31, the company has begun a market acceptance test and received positive preliminary feedback, including the streamlining of the delivery device triggering mechanism and the reduction of waste. Teleflex is currently increasing manufacturing levels for the product ahead of the full commercial launch slated for early 2021. Regarding the UroLift ATC, the market acceptance test is well underway.

In the third quarter, the Vascular Access segment reported 6.8% growth on robust performances of PICC and EZ-IO products.  COVID-19 positively impacted the growth rates of vascular products during the third quarter by approximately 1%.

Over the past six months, Teleflex’s stock has underperformed its industry. The stock has gained 2.5% compared with the industry's 15.5% growth.

Stocks to Consider

Some better-ranked stocks from the broader medical space are ResMed RMD, Thermo Fisher Scientific TMO and Align Technology ALGN.

ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2.

Align Technology’s long-term earnings growth rate is estimated at 18.3%. It currently carries a Zacks Rank #2.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
Teleflex Incorporated (TFX) : Free Stock Analysis Report
 
Align Technology, Inc. (ALGN) : Free Stock Analysis Report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research